AGP Executive Report
Last update: 6 hours agoBiotech Deal for Liechtenstein-linked markets: SERB Pharmaceuticals has signed to buy exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma for €115m ($133.6m), covering the EU plus Liechtenstein, Norway, Switzerland, the UK and the Middle East & North Africa. Transplant-focused medicine: Idefirix is used to desensitise highly sensitised adult kidney transplant candidates with reactive IgG antibodies, lowering rejection risk before transplant. Deal structure: Hansa gets €110m upfront and a further €5m when the EMA accepts the full approval filing; SERB will handle long-term follow-up and paediatric research after it becomes the market authorisation holder. Next steps: the transaction awaits regulatory clearances, with completion expected within 60 days.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
